Statin Myopathy
a*onDepartmentUniversityofBridgeport operlyrecordthefindings. earningObjec*ves /diagnosisofpiriformissyndrome. hyandpiriformissyndrome.OpeningStatement MyopathyMyopathy efiber. Diagnosisisthekeytosuccessfultreatment! �ness,andspasm.1
ascularDisease Sta*ns(orHMG- wercholesterollevelsbyinhibi*ngtheenzymeHMG- entoftotalcholesterolinthebody. oodpressure:ameta- 9.CoronaryArteryDisease rdiovasculardisease(CVD). oodpressure:ameta- 9.CoronaryHeartDisease Hydroxymethylglutaryl- ‐coenzymeA(HMG- onaryheartdiseaseandatherosclerosis.2
1/28/15AngioplastyPreandPostStentImages ��owthroughtheartery.BenefitsofSta*ns farteriesleadingtotheheartorbrain. JOHND.ABRAMSON.HarvardSchoolofMedicineCaveatEmptor uallyreducecardiovasculardisease. e,anunhealthydiet,andotherlifestylefactors. er13,2013AdverseDrugReac*ons ociatedwithHMG- olesterolaemiaisofparamountimportance. ;5(5):651- ‐66.PhysicianDenialEighty- eirsymptom.3
1/28/15PhysicianDenial pathysurvey,86%vs14%musclesurvey;p 10(- ‐8)foreach). thepossibilityofaconnec*on. eporters,poten*allyspeedingrecogni*onofADRs. 30(8):669- geffects:implica*onsforpa*ent- ‐targetedadverseeffectsurveillance.Muscle- ‐RelatedAdverseEffects(MAE) Threehundredfiry- ‐fourpa*ents(agerange34- ‐86yrs)whoself- ‐reportedmuscle- ngratesMuscle- ‐RelatedAdverseEffects(MAE) Pa*entswithperceivedsta*n- e(QOL). Pharmacotherapy.2010Jun;30(6):541- ‐53.QualityofLifeMuscle- ‐RelatedAdverseEffects(MAE) ose'withoutwhichnomemberofthehumanracecanbehappy.' p 0.01). ks);someMAEsoccurredarerlong- ‐termsymptom- ‐freeuse. earch2,pp229- ‐248. ChamS,EvansMA,DenenbergJO,GolombBA.Sta*n- ‐associatedmuscle- Pharmacotherapy.2010Jun;30(6):541- ‐53.4
1/28/15Muscle- ‐RelatedAdverseEffects(MAE) latencytoonset(median2wks). Ldomains.Muscle- ‐RelatedAdverseEffects(MAE)CONCLUSION: Thedataindica*ngadose- sidera*onforameliora*ngsymptoms. ChamS,EvansMA,DenenbergJO,GolombBA.Sta*n- ‐associatedmuscle- Pharmacotherapy.2010Jun;30(6):541- ‐53. Muscle- uralhistoryofsta*n- - ‐associatedmuscle- Pharmacotherapy.2010Jun;30(6):541- ‐53.CaseReport A63year- ermanentheartdamage.5
y2- lepainsandpiriformissyndromePiriformisSyndrome some*mesintothemedialfoot. osisandtreatment.MuscleNerve.2009;40(1):10- ‐18.doi:10.1002/mus.21318.ClinicalChallenge ptomsofPiriformisSyndrome tandfromseatedorsquawngposi*on b Changeofposi*ondoesnotrelievepaincompletely Increasingpainarersiwngforlongerthan15- ‐20minutes(mostcommonsymptom)6
1/28/15SymptomsofPiriformisSyndrome Syndrome Sta*nholidayanddetermineresponse response sponse on*nueandswitchtoniacin andatorySignsofPiriformisSyndrome formismuscle Palpablemassinipsilateralbu]ock Asymmetricalweaknessofaffectedlimb ysigns Ipsilateralleglengthinequality Glutealatrophy(chroniccasesonly)Discussion talcondi*onsandtakingsta*nmedica*ons ClosingStatement Diagnosisisthekeytosuccessfultreatment!7
1/28/15 6 Muscle(Pain(and(Piriformis(Syndrome(Approximately& 2_4&weeks&post surgery&the& paent experienced& severemuscle& pai
Statin Intolerance in the Elderly: A Focus on Myopathy Management Elizabeth Cook, PharmD, AE-C, BCACP, CDCES . The speakers of this CE activity, E. Cook and C. McLain, have no actual . Pharmacist Patient Care Process Collect Assess Plan Monitor &
Myasthenia gravis Lambert-Eaten myasthenic syndrome Organophosphate poisoning Muscle Polymyositis, dermatomyositis, critical illness myopathy, rhabdomyolysis Acid maltase deficiency, congenital myopathy, congenital muscular dystrophy, Duchenne muscular dystrophy, Limb girdl
the Heart Rhythm Society Eric N. Prystowsky Fellowship Award. Gentaro Ikeda, MD was awarded a Stanford Dean’s Fellowship Grant. June-Wha Rhee, MD was awarded a US Department of Defense Peer Reviewed Medical Research Program Discovery Award focusing on studying Statin Myopathy. Mahmood Alhusseini, MS was a European Heart Rhythm Association
primary care provider to communicate my diagno-sis. Because I'm a member of the medical staff with full access to the electronic health care record, I am able to efficiently communicate my concerns to the prescribing primary care provider. Since the majority of chiropractic physicians practice as solo practitioners or as associates in
Lloyd-Jones DM, et al. J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. Statin decision first Consider adherence, statin tolerance, control of risk factors Consider percentage LDL-C & non-HDL-C reduction and level achieved Consider ezetimibe, bile acid sequestrants, PCSK9i
2018 Kaiser Permanente Care Management Institute Diabetes, Aged 40-75 Years, and LDL-C 70-189 mg/dL } Initiate or continue moderate-intensity statin therapy. Consider high-intensity statin therapy for adults with diabetes and 10-year ASCVD risk 7.5%. } If aged 40 or 75 years, consider evaluating the potential for ASCVD risk-
Plan: Continue Zetia 10 mg daily (recently started) Add Crestor 5 mg 3 days a week, with plans to titrate up as tolerated 68 y/o presents to the lipid clinic for hyperlipidemia, secondary prevention, and statin intolerance. Update after phone call 2 weeks after starting Crestor Significant
Welcome to the ASME/Bath 2019 Symposium on Fluid Power and Motion Control (FPMC 2019) held at the Zota Beach Resort, on the powdery white sands and brilliant turquoise waters of Sarasota’s Longboat Key, Florida. I hope you will find the technical program of the symposium engaging. I also hope that you will enjoy the social events and further develop your network with colleagues. The .
